The pharmaceutical industry is facing increasing complexity in market access, driven by rising drug development costs, stringent regulatory hurdles, and shifting payer expectations. Developing a robust market access strategy is essential for ensuring that innovative therapies reach patients quickly and remain accessible across diverse markets.
Key Challenges in Market Access
While innovation in drug development is accelerating, the path to market remains fraught with obstacles that can delay or restrict patient access to new treatments. These challenges stem from both external market dynamics and internal inefficiencies within the commercialization process.
1. Regulatory Delays: Regulatory agencies, such as the FDA and EMA, have diverse approval processes that can delay market entry. To illustrate, in December 2024, the FDA declined approval for J&J’s subcutaneous version of Rybrevant, used in EGFR-mutated non-small cell lung cancer.
2. Pricing and Reimbursement Issues: Global price negotiations and the rise of value-based pricing are challenging companies to strike a balance between affordability and profitability. For example, recent legislative changes, like the U.S. Inflation Reduction Act, directly impact pricing strategies.
3. Market Competition: The entry of biosimilars and generics increases competition, especially for biologics. Companies must differentiate their therapies based on clinical value, patient adherence, and real-world evidence.
Strategies to Overcome These Challenges
To successfully overcome market access barriers, pharmaceutical companies must adopt a multi-pronged, forward-thinking approach. Early stakeholder engagement is critical—by involving regulators, payers, and healthcare providers from the initial stages of drug development, pharmaceutical companies can align on evidence requirements and accelerate the approval process. Simultaneously, leveraging real-world evidence (RWE) helps strengthen the value proposition of a therapy by validating its effectiveness and safety in routine clinical practice, which is essential for supporting informed payer decisions in the market access pharma landscape.
Health Economics and Outcomes Research (HEOR) further complements this by quantifying the economic and quality-of-life benefits of treatments, thereby forming a compelling foundation for reimbursement outcomes-related discussions. Additionally, adaptive pricing models—such as value-based pricing or outcome-based agreements—enable flexible, outcome-driven solutions that are particularly relevant in resource-constrained markets.
Collectively, these strategies ensure that innovative therapies not only reach the market efficiently but also maintain long-term accessibility and viability within the complex ecosystem of market access pharma.
Discover how our integrated market access strategy enabled a U.S.-based pharmaceutical company to overcome regulatory delays and pricing hurdles for its oncology therapy. This strategy not only accelerated approval timelines but also ensured broader patient access across key markets.
Fill out the form to access the complete case study.
